Search

Arcus Biosciences Inc

Fechado

SetorSaúde

24.06 -2.08

Visão Geral

Variação de preço das ações

24h

Atual

Mín

23.98

Máximo

24.93

Indicadores-chave

By Trading Economics

Rendimento

37M

-91M

Vendas

24M

41M

EPS

-0.72

Margem de lucro

-221.951

Funcionários

601

EBITDA

38M

-85M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+56.97% upside

Dividendos

By Acuity

Próximos Ganhos

26 de out. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

257M

3.7B

Abertura anterior

26.14

Fecho anterior

24.06

Arcus Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de set. de 2026, 20:21 UTC

Arcus Biosciences Inc shares are lower in after-market hours, marking seven consecutive sessions of declines. No specific news was identified for the price movement.

11 de set. de 2026, 21:21 UTC

Arcus Biosciences Inc shares are lower in after-market trading, continuing a recent trend. No specific company news was identified to explain the decline.

10 de set. de 2026, 20:01 UTC

Arcus Biosciences Inc shares are sharply lower today, breaking a recent trend of higher closes. Unusually high trading volume may be influencing the decline.

9 de set. de 2026, 20:07 UTC

News

Shares of Arcus Biosciences are lower today, despite anticipation of a significant data update in October following a recent presentation at Citigroup's summit.

8 de set. de 2026, 20:07 UTC

Arcus Biosciences Inc shares are lower today, continuing a decline since Friday's close. The stock is trading near the lower end of its one-month range.

2 de set. de 2026, 20:08 UTC

Correlated Moves

Arcus Biosciences Inc. shares are higher today, supported by gains in the biotechnology sector and trends in related ETFs. The stock has stabilized after fluctuations.

28 de ago. de 2026, 20:02 UTC

Arcus Biosciences shares are lower today, breaking a trend of higher closes. Rising U.S. Treasury yields may be impacting investor sentiment in biotechnology.

26 de ago. de 2026, 20:08 UTC

Arcus Biosciences Inc shares are lower during Wednesday's session amid mixed market performance and inflation data, with no specific company news identified for the decline.

20 de ago. de 2026, 19:36 UTC

Correlated Moves

Arcus Biosciences shares are lower, reflecting a broader decline in the biotechnology sector amid first-quarter results indicating a notable drop in price.

19 de ago. de 2026, 19:46 UTC

Correlated Moves

Arcus Biosciences Inc is trading higher, supported by a positive trend in the biotechnology sector. The stock remains above its 20-day moving average.

18 de ago. de 2026, 20:06 UTC

Arcus Biosciences Inc. shares are trading roughly flat amid no specific news. The stock remains above its 20-day moving average.

17 de ago. de 2026, 19:16 UTC

News

Arcus Biosciences Inc is rising as biotechnology sector momentum continues. The company reported second-quarter revenue of $41 million and a net loss of $91 million.

14 de ago. de 2026, 19:46 UTC

Arcus Biosciences Inc is higher today, continuing a positive trend since Thursday's close. The stock remains above its 20-day moving average.

11 de ago. de 2026, 19:56 UTC

News

HC Wainwright raised Arcus Biosciences' Q3 2026 EPS estimate to -$1.00 and maintained a "Buy" rating with a price target of $45.00.

10 de ago. de 2026, 21:02 UTC

Arcus Biosciences Inc shares are higher in after-market trading, continuing a strong upward trend since Monday's close, well above the 20-day moving average.

7 de ago. de 2026, 19:36 UTC

Arcus Biosciences Inc. shares are higher today, trading within a typical range amid investor uncertainty over future monetary policy following a weak jobs report.

6 de ago. de 2026, 20:03 UTC

News

Arcus Biosciences shares are higher as Wells Fargo raises its price target to $23.00 and Wedbush increases its target to $43. Trading volume is notably high.

5 de ago. de 2026, 20:21 UTC

News

Arcus Biosciences reported a net loss of $91 million but exceeded revenue expectations with $41 million. Shares are higher in after-market trading.

4 de ago. de 2026, 21:02 UTC

Arcus Biosciences Inc shares are higher in after-market trading, reflecting positive market sentiment amid easing inflation concerns from U.S.-Iran negotiations.

3 de ago. de 2026, 19:36 UTC

Arcus Biosciences shares are lower today, reflecting broader market dynamics and geopolitical developments impacting investor sentiment. Earlier, shares peaked before declining.

31 de jul. de 2026, 23:16 UTC

Arcus Biosciences Inc. shares are lower in after-market hours, continuing a trend of declining prices and remaining below the 20-day moving average.

30 de jul. de 2026, 18:03 UTC

Arcus Biosciences Inc gains today, supported by a broader market uptick despite geopolitical tensions and inflation concerns. Shares pulled back from earlier session highs.

29 de jul. de 2026, 19:56 UTC

Macro Event

Arcus Biosciences shares are lower amid broader market pressures from steady interest rates and rising crude oil prices, marking five consecutive sessions of decline.

28 de jul. de 2026, 20:06 UTC

Arcus Biosciences Inc shares are lower today, reflecting broader market trends and declines in Asian markets, including significant losses in the Nikkei 225 Index.

27 de jul. de 2026, 21:01 UTC

Arcus Biosciences Inc shares declined in after-market hours, continuing a downward trend over the last four sessions. No specific news was identified to explain the move.

24 de jul. de 2026, 19:06 UTC

News

Arcus Biosciences has signed a clinical supply agreement with AVEO to evaluate casdatifan with tivozanib. Shares are trading lower, reflecting unusual weakness.

22 de jul. de 2026, 20:13 UTC

Arcus Biosciences shares are higher in after-market hours. Broader market volatility is influenced by rising crude oil prices and geopolitical tensions.

21 de jul. de 2026, 19:36 UTC

Arcus Biosciences shares are higher today, supported by overall market strength and positive sentiment in the biotechnology sector. The stock has advanced notably since Monday.

20 de jul. de 2026, 18:06 UTC

News

H.C. Wainwright raised Arcus Biosciences' price target to $45 from $32, maintaining a Buy rating. Shares are higher today following the analyst's upgrade.

Comparação entre Pares

Variação de preço

Arcus Biosciences Inc Previsão

Preço-alvo

By TipRanks

56.97% parte superior

Previsão para 12 meses

Média 38.6 USD  56.97%

Máximo 47 USD

Mínimo 23 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcus Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

10 ratings

7

Comprar

3

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat